Psychogenics Inc.
Paramus, NJ Part of PGI Holding Corporation
- UEI
- YXMNA8N7LFG4
- CAGE
- 8HHD9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, PGI Holding Corporation, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
WZ4JEKPZXJ87
-
Parent
WZ4JEKPZXJ87
- SAM.gov registration date
- Physical address
- 215 College Rd, Paramus, NJ 07652, USA
- Website
- psychogenics.com
- Founded
- 1999
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $14,781,625 |
| FY2025 | $9,482,040 |
| FY2024 | $11,772,171 |
| FY2023 | $9,330,655 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $14,781,625 |
Contract awards
Grant awards
Similar vendors
About the company
Psychogenics Inc., a for-profit preclinical contract research organization based in Paramus, New Jersey, provides specialized phenotypic drug screening and preclinical development services to the National Institutes of Health as a prime contractor, operating under a Total Small Business set-aside designation on its largest federal vehicle. The vendor operates as a subsidiary of PGI Holding Corporation and competes exclusively on prime awards across four NIH institutes, with no subcontract or sub-award activity in the federal portfolio.
Psychogenics' capability portfolio centers on in-vivo and in-vitro phenotypic screening platforms — SmartCube and eCube — designed to identify efficacy, pharmacokinetics, side effects, and abuse liability of investigational agents across complex disease models including pain, addiction, neurodegeneration, and psychiatric disorders. The vendor's representative work includes a $65.84 million Total Small Business delivery order awarded by the National Institute of Neurological Disorders and Stroke on September 6, 2024, under the Preclinical Screening Platform for Pain (PSPP), an $80 million single-award indefinite delivery contract running through September 2029 that supports the NIH's Helping to End Addiction Long-term (HEAL) initiative. Psychogenics also holds a $2.14 million non-set-aside delivery order from NINDS for target engagement of investigational agents in PSPP (awarded September 15, 2023, completed September 14, 2024). Federal grant work includes a $398,947 project grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 15, 2026, for preclinical evaluation of novel molecules as potential treatments for cocaine use disorder, a $495,699 project grant from the National Institute on Aging (CFDA 93.866) awarded September 20, 2025, for development of PGI-5128 to treat agitation in Alzheimer's disease, and two Small Business Innovation Research project grants from the National Institute of Mental Health (CFDA 93.242) totaling development of machine-learning platforms for phenotypic drug design and EEG signature analysis for drug repurposing in rare diseases.
Customer concentration is absolute: the National Institute of Neurological Disorders and Stroke accounts for all $245.6 million in combined potential value across six awards (60% of potential value obligated as of the snapshot date), while the National Institute of Mental Health, National Institute on Drug Abuse, and National Institute on Aging together hold the remaining four awards. Psychogenics' federal footprint is entirely contract and grant work — no IDIQs, GWACs, or BPAs. The vendor operates two single-award indefinite delivery contracts with NINDS: one with a $49.9 million ceiling (IDC 75N95019D00026) generating three task orders and one with an $80 million ceiling (IDC 75N95024D00038) generating one task order totaling $65.84 million. Four of ten awards reach ultimate completion within the next twenty-four months, representing recompete exposure. Activity has been episodic — three awards in 2019, two in 2023, three in 2024, declining to one award in 2025 and one in 2026 — with $89.3 million obligated against $245.6 million in potential value, indicating early-stage execution on large vehicle ceilings.
Quick answers
Is Psychogenics Inc. registered in SAM.gov?
Yes. Psychogenics Inc.'s SAM.gov registration is active through June 15, 2027.
How much has Psychogenics Inc. received in federal contracts?
Federal contracts obligated $9,482,040 to Psychogenics Inc. in fiscal year 2025 and $45,366,491 in fiscal years 2023 through 2027.
How does Psychogenics Inc. rank among federal contractors?
Psychogenics Inc.'s parent company, PGI Holding Corporation, ranked #9 in PSC AN11, #41 in NAICS 541714 and #87 in PSC AN in FY2025.
What is Psychogenics Inc.'s most recent federal award?
Psychogenics Inc.'s most recent federal grant award is TAAR1 agonists for the treatment of stimulant use disorder (R43DA061847), from National Institute on Drug Abuse (NIH), on June 15, 2026.
On GovTribe
See Psychogenics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors